-
Mashup Score: 14Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran - 19 day(s) ago
Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Despite the approval of nonstatin therapies for LDL‐C lowering ove…
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 16Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials - 3 month(s) ago
Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol.The purpose of this study was to provide reliable evidence to…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8Inclisiran and cardiovascular events: a comprehensive... : Current Opinion in Cardiology - 6 month(s) ago
an significantly lowers LDL-C levels, as shown by phase III studies, by inhibiting hepatic synthesis of proprotein convertase subtilisin kexin 9 (PCSK-9), a protein implicated in the degradation of LDL receptors. Inclisiran has the benefit of subcutaneous injection twice a year, which may reduce patient nonadherence when compared with other LDL-C reducing therapies such as statins and ezetimibe, which require daily dosing. When added on top of statins, a greater proportion of patients achieved recommended cholesterol goals. It has also demonstrated a good safety profile with few adverse effects. Summary Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Although it has been demonstrated to be effective in decreasing LDL-C, further research is n
Source: journals.lww.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Local GP leaders across the south of England have told practices not to follow the NHS’s advice to prescribe the cholesterol lowering drug inclisiran because of concerns over funding and long term safety monitoring. The pushback comes amid a drive by NHS England, which published funding guidance in April 2023,1 and local integrated care boards (ICBs) to make the drug available in primary care to help tackle cardiovascular disease. The National Institute for Health and Care Excellence (NICE) approved inclisiran—made by Novartis and marketed as Leqvio—in 2021,23 hailing it as “a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.” Administered by injection, inclisiran uses RNA interference to boost the liver’s ability to remove low density lipoprotein cholesterol (LDL-C) from the blood. However, the BMA, the Royal College of General Practitioners,45 and experts writing in The BMJ 6 have raised concerns about inclisiran being ini
Source: www.bmj.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Source: www.thelancet.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 14A new strategy for ldl-c lowering and prevention of ASCVD | VHRM - 9 month(s) ago
Providing an overview of the use of inclisiran, reviewing current trial data, and outlining an approach to potential patient selection. Read more
Source: www.dovepress.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7
Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice
Source: www.minervamedica.itCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Novartis scraps UK heart attack prevention trial - 12 month(s) ago
Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.
Source: ReutersCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Novartis Scraps UK Heart Attack Prevention Trial - 1 year(s) ago
Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.
Source: MedscapeCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Novartis scraps UK heart attack prevention trial - 1 year(s) ago
Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.
Source: ReutersCategories: Cardiologists, Latest HeadlinesTweet
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of #Inclisiran. An overview. Ongoing trials to convince the last skeptics : VICTORION-2P and VICTORION-plaque. https://t.co/71cE4iUAit